Before we begin, I advise you that we will be making forward-looking statements today based on our current expectations and beliefs, including, but not limited to potential market sizes and market share; market trends; impact of ACIP recommendations and timing of such impact; financial guidance and trends, including revenue, profitability, and sufficiency of current capitalization; timing and results of clinical trial starts and data readouts and potential future uses of CpG 1018 adjuvant. Joining me on the call today are Ryan Spencer, chief executive officer; Donn Casale, senior vice president of commercial; Rob Janssen, chief medical officer; and Kelly MacDonald, chief financial officer.